COMPASS PATHWAYS PLC Proceeds from Long-Term Debt Issued
COMPASS PATHWAYS PLC (CMPS) reported Proceeds from Long-Term Debt Issued of $18.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-08-05
- COMPASS PATHWAYS PLC proceeds from issuance of long-term debt for the quarter ending 2026-06-30 was $0.00.
- COMPASS PATHWAYS PLC proceeds from issuance of long-term debt for the quarter ending 2026-03-31 was $18.58M.
- COMPASS PATHWAYS PLC proceeds from issuance of long-term debt for the quarter ending 2025-06-30 was $0.00.
- COMPASS PATHWAYS PLC proceeds from issuance of long-term debt for the quarter ending 2025-03-31 was $0.00.
- COMPASS PATHWAYS PLC proceeds from issuance of long-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- COMPASS PATHWAYS PLC proceeds from issuance of long-term debt for fiscal 2023 was $29.59M.
- COMPASS PATHWAYS PLC proceeds from issuance of long-term debt for fiscal 2022 was $0.00.
- COMPASS PATHWAYS PLC proceeds from issuance of long-term debt for fiscal 2021 was $0.00.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $18.58M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | $18.58M 10-Q · filed 2026-05-13 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $29.59M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $29.59M 10-Q · filed 2024-10-31 | ||
| 2023-06-30 | $29.59M 10-Q · filed 2024-08-01 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |